期刊文献+

化疗相关性恶心与呕吐的治疗进展 被引量:9

下载PDF
导出
摘要 恶心和呕吐是肿瘤病人化疗时最常出现的不良反应。根据恶心、呕吐出现时间的不同,将化疗相关性恶心、呕吐分为急性、延迟性及预期性3种类型。5-羟色胺受体拮抗剂与糖皮质激素的联合应用可将急性恶心、呕吐的控制率提高到70%,但延迟性恶心、呕吐的发生率仍高达40%。而速激肽NK1受体拮抗剂的问世显著提高了化疗相关性恶心、呕吐的控制率,尤其是延迟性恶心、呕吐的发生率显著降低。目前,5-羟色胺受体拮抗剂、地塞米松及速激肽NK1受体拮抗剂三者联用为标准止吐方案。本文就止吐药物在肿瘤病人中的应用做一简单综述。
作者 王转转 卢愿
出处 《齐鲁医学杂志》 2013年第2期186-188,共3页 Medical Journal of Qilu
  • 相关文献

参考文献18

  • 1ETTINGER D S, BIER MAN P J, BRADBURY B, et al. Antemesis[J]. J Natl Compr Cone Netw, 2007,5 (1) : 12-13. 被引量:1
  • 2BALU S, BUCHNER D, CRAVER C, et al. Palonosetron versus other 5-HT3 receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting[J].Clin Ther, 2011,33(4) :443-455. 被引量:1
  • 3VIDALL C, DIELENSEGER P, FARRELL C, et al. Evidence-based management of chemotherapy-induced nausea and vomiting : a position statement from a European cancer nursing forum[J].Ecancer, 2011,5 : 211. 被引量:1
  • 4DEWAN P, SINGHAL S, HARIT D. Management of chemotherapy-induced nausea and vomiting[J]. Indian Pediatr, 2010, 47(2) :149-155. 被引量:1
  • 5AAPRO M S, GRUNBERG S M, MANIKHAS G M, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy[J].Ann Oncol, 2006,17(9) :1441-1449. 被引量:1
  • 6JORDAN K, KASPER C, SCHMOLL H J. Chemotherapy-induced nausea and vomiting: current and new standards in the ant emetic prophylaxis and treatment[J]. Eur J Cancer, 2005, 41(2) :199-205. 被引量:1
  • 7HERRSTEDT J, DOMBERNOWSKY P. Anti-emetic therapy in cancer chemotherapy: current states[J]. Basic Clin Pharmacol Toxicol, 2007,101 (3) : 143-150. 被引量:1
  • 8TRIGG M E, HIGA G M. Chemotherapy-induced nausea and vomiting: ant emetic trials that impacted clinical praetice[J]. J Oncol Pharm Pract, 2010,16(4):233-244. 被引量:1
  • 9JORDAN K, SCHMOLL H J, AAPRO M S, Comparative activity of ant emetic drugs[J]. Crit Rev Oncol Hematalo, 2007, 61(2) : 162-175. 被引量:1
  • 10ROJAS C, SLUSHER B S. Pharmacological mechanisms of 5- HT3 and taehykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting[J], Eur J Pharmacol, 2012,684(1-3) :1-7. 被引量:1

二级参考文献6

  • 1修元德.肿瘤化疗的止吐治疗[J].齐鲁医学杂志,2006,21(4):374-376. 被引量:21
  • 2AAPRO M S.Palonosetron as an anti-emetic and anti-nausea agent in oncology[J].Clin Risk Manag,2007,3 (6):1009-1020. 被引量:1
  • 3SIDDIQUI M A,SCOTT L J.Palonosetron[J].Drugs,2004,64(10):1125-1132. 被引量:1
  • 4STOLTZ R,CYONG J C,SHAH A,et al.Pharmacokinetic and safety evaluation of palonosetron,a 5-hydroxytryptmine-3receptor antagonist,in U S and Japanese health subjects[J].J Clin Pharmacol,2004,44(5):520-531. 被引量:1
  • 5EISENBERG P,MACKINTOSH F R,RICH P,et al.Efficacy,safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy:a dose-ranging clinical study[J].Ann Oncol,2004,15 (2):330-337. 被引量:1
  • 6李志强,徐建明,刘端祺,张贺龙,王宝成,张沂平,欧阳学农,陈正堂,陶敏,高亚杰,王岩,李晓玲,刘烈军.盐酸帕洛诺司琼预防中重度化疗致吐药引起恶心呕吐的Ⅱ期临床研究[J].临床肿瘤学杂志,2009,14(6):487-490. 被引量:36

共引文献1

同被引文献104

引证文献9

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部